ReviewJournal of inflammation research2026
Inflammatory Endotypes of Chronic Rhinosinusitis and Impacts on Comorbid Asthma.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis (CRS) and asthma frequently coexist and are increasingly understood as manifestations of a shared "united airway" inflammatory process. However, clinical heterogeneity remains substantial, and conventional phenotyping alone does not reliably predict disease trajectory or treatment response across the upper and lower airways. Endotype-based classification, particularly differentiation of type 2 and non-type 2 inflammation, offers a framework that can refine prognostication and support more individualized management. This review synthesizes current evidence linking CRS inflammatory endotypes with asthma severity, exacerbation risk, and postoperative or medical outcomes. We summarize practical biomarkers used in routine care and research settings and discuss how these markers inform therapeutic decisions in CRS with comorbid asthma. In type 2 disease, endotype and biomarker profiles can support a more individualized treatment approach, while also informing escalation pathways in patients with persistent symptoms or recurrence, including consideration of biologic therapy in carefully selected cases. We also highlight limitations of current approaches, including overlap between inflammatory patterns, variability between tissue and systemic biomarkers, and the still-evolving definition of non-type 2 CRS, all of which can limit precision medicine in routine clinical decision-making. Future priorities include standardization of endotype definitions, validation of pragmatic biomarker panels, and integrated multidisciplinary pathways that align upper- and lower-airway outcomes. A biology-informed stratification approach may ultimately enable better patient selection for surgery, corticosteroid strategies, and biologics, improving long-term control of both CRS and asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.